Health and safety are always the top priority at Camp Barney Medintz, the residential camp of the Marcus Jewish Community Center of Atlanta (MJCCA). After having to make the difficult but necessary decision to not open camp in the summer of 2020, Camp Barney Medintz knew that one critical component of opening in the Summer of 2021 would be a comprehensive COVID-19 testing program.
Camp Barney Medintz turned to Healthcare IT Leaders, BD, and TrackMy™ Solutions for COVID-19 testing services. Healthcare IT Leaders worked closely with Camp Barney Medintz to develop and implement a COVID-19 testing strategy utilizing test result notification technology from TrackMy Solutions and rapid antigen testing with the BD Veritor™ Plus System.
On the first day of each session, Healthcare IT Leaders conducted COVID-19 rapid antigen tests from BD on every camper. Results were provided in 15-20 minutes through an app from TrackMy Solutions. A second COVID-19 test was administered later in each session.
“In preparing for Summer 2021, we convened an advisory group comprised of expert public health and medical professionals and closely monitored all guidance from local, state, and national agencies, as well as the American Camp Association,” said Jim Mittenthal, Camp Barney Medintz Director. “Efficient and accurate COVID-19 testing was a crucial part of our reopening plan, and we are grateful for our partnership with Healthcare IT Leaders. The testing process was seamless and the rapid results instrumental to a smooth summer.”
About Healthcare IT Leaders
Healthcare IT Leaders is a national leader in IT consulting and workforce solutions, connecting healthcare organizations with experienced technology talent for implementation services, project management, consulting, and full-time hiring. Our COVID-19 practice, Healthy Returns, delivers COVID-19 testing, contract tracing, and vaccination services for leading businesses and schools. Based in Greater Atlanta, our company ranked #1 for Business Solutions in the 2020 Best of KLAS Report, ranked 5 consecutive years on the Inc. 5000 five consecutive years, and has been named a Best Place to Work by the Atlanta Business Chronicle. For more information, visit www.healthcareitleaders.com and www.healthyreturns.info.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at linkedin.com/company/bd1 and Twitter @BDandCo.
*The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 is intended for the qualitative detection of SARS-CoV-2 nucleocapsid antigens in direct anterior nasal swabs from individuals who are either suspected of COVID-19 by their health care provider within the first five days of the onset of symptoms, or from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests.
This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
About TrackMy Solutions
TrackMy Solutions, in executing our vision of Saving Lives through technology, has created a game-changing healthcare platform for tracking COVID-19 Health and Safety for employers, universities and mass public health sites. Complete with full end to end COVID19 testing and vaccination workflows, from Registration, Scheduling and Point of Administration test/vaccination administration capture (with creation of the proprietary TrackMy eLab Result/eVaccine Passport for users/patients), through to reporting results directly to the state-registry (to meet regulatory compliance), and offers complete 3rd party billing integration and processing (health reimbursement), along with point-of-sale functionality to capture for user direct payments as necessary– all securely built in the AWS Cloud. Learn more at www.trackmysolutions.us.